Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole

BACKGROUND: KW-2450 is an oral dual insulin-like growth factor-1 receptor/insulin receptor tyrosine kinase inhibitor. We investigated the in vitro and in vivo preclinical activity of KW-2450 plus lapatinib and letrozole and conducted a phase I trial of the triple-drug combination in one male and 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Umehara, Hiroshi, Maekawa, Yoshimi, Koizumi, Fumito, Shimizu, Makiko, Ota, Toshio, Fouad, Tamer M., Willey, Jie, Kaito, Hidekuni, Shiraishi, Norihiko, Nakashima, Daisuke, Akinaga, Shiro, Ueno, Naoto T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066809/
https://www.ncbi.nlm.nih.gov/pubmed/30083253
http://dx.doi.org/10.1177/1758835918786858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6066809/
https://www.ncbi.nlm.nih.gov/pubmed/30083253
http://dx.doi.org/10.1177/1758835918786858

Ejemplares similares